LGM
AVTX icon

Logos Global Management’s Avalo Therapeutics AVTX Stock Holding History

Logos Global Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.3M Buy
1,150,000
+850,000
+283% +$13.4M 0.91% 34
2026
Q1 		$4.48M Buy
+300,000
New +$4.69M 0.22% 57
2024
Q4 		– Sell
-539,079
Closed -$5.12M – 50
2024
Q3 		$5.12M Hold
539,079
– – 0.55% 42
2024
Q2 		$6.72M Buy
+539,079
New +$6.99M 0.54% 43

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Logos Global Management's AVTX Position: Q2 2026 in Review

Logos Global Management increased its Avalo Therapeutics (AVTX) stake by 283% in Q2 2026, buying an estimated $13.4M and bringing the position to 1,150,000 shares worth $21.3M. The position accounts for 0.91% of the portfolio, ranked #34.

Logos Global Management first reported a position in AVTX in Q2 2024 and has held it in 4 quarters since. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Logos Global Management held 1,150,000 shares of Avalo Therapeutics worth $21.3M as of Q2 2026.
  • Logos Global Management bought 850,000 Avalo Therapeutics shares in Q2 2026, an estimated $13.4M.
  • Avalo Therapeutics made up 0.91% of Logos Global Management's portfolio in Q2 2026, its #34 holding.
  • Logos Global Management first reported a position in Avalo Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.